ATPLEX

• Sodium bicarbonate: 7 mg
• Dimethylglycine: 50 mg
• Phosphocreatine: 50 mg
• L-Carnitine: 75 mg
• Citicoline: 90 mg
• ATP: 10 mg

ATPLEX is evaluated as a combined formulation rather than a single active compound. Each component contributes to research-relevant biochemical pathways: The combined formulation is explored in research involving acute energy availability, phosphagen recycling, buffering capacity, mitochondrial function, and choline-dependent membrane and signaling biology.

• Sodium bicarbonate: Studied as a buffering agent in models examining acid-base balance, lactate-related dynamics, and high-intensity performance endpoints
• Dimethylglycine: Investigated in methylation-adjacent and one-carbon-metabolism paradigms, where it may influence methyl-donor availability and metabolic-stress tolerance
• Phosphocreatine: Studied as a phosphagen-system substrate supporting rapid ATP regeneration, short-duration energy production, and cellular energy resilience
• L-Carnitine: Investigated for its role in transporting long-chain fatty acids into mitochondria and supporting mitochondrial energy metabolism, particularly when substrate utilization is a primary variable
• Citicoline: Studied as a choline-pathway intermediate involved in phospholipid synthesis and cholinergic signaling, commonly investigated in neurometabolic and membrane-biology research
• ATP: Evaluated as an energy-related substrate in controlled models, typically examined in the context of cellular energy availability and bioenergetic signaling

ATPLEX is commonly studied in

• Phosphagen-system and short-duration performance models
• Cellular energetics and ATP-regeneration research
• Acid-base balance and buffering paradigms during high-intensity metabolic stress
• Mitochondrial substrate utilization and fatty-acid-transport studies
• Choline-related membrane dynamics and neurometabolic signaling
• Integrated performance models in which multiple energy-system inputs are intentionally combined

Reported observations are component- and model-dependent and may include

• Gastrointestinal discomfort in buffering-focused paradigms where sodium bicarbonate is a primary variable
• Headache-like or stimulation-like effects in models sensitive to cholinergic-pathway modulation
• Confounded outcomes when combined with additional creatine-system interventions, potent stimulants, or other performance-enhancing variables that overlap with fatigue and output endpoints
• Difficulty attributing observed effects to individual components without structured single-variable comparator groups

ATPLEX is often explored alongside interventions that overlap with its primary mechanistic pathways.